Výsledky vyhledávání

Akademický článek

Alosetron use in clinical practice: significant improvement in irritable bowel syndrome symptoms evaluated using the US Food and Drug Administration composite endpoint

Autor: Brian E. Lacy, Jean Paul Nicandro, Emil Chuang, David L. Earnest

Publikováno v: Therapeutic Advances in Gastroenterology, Vol 11 (2018)

Background: Alosetron is approved to treat women with severe IBS and diarrhea (IBS-D) who have failed standard therapy. In our study, we aimed to evaluate alosetron efficacy using new US Food and Drug Administration (FDA) endpoints and utilization in

Externí odkaz: https://doaj.org/article/ecbfd7e16ae5449da4cd9c89d60b4ece

Zobrazit plný text záznamu

Akademický článek

Molecular Pathophysiology of Epithelial Barrier Dysfunction in Inflammatory Bowel Diseases

Autor: Jessica Y. Lee, Valerie C. Wasinger, Yunki Y. Yau, Emil Chuang, Vijay Yajnik, Rupert WL. Leong

Publikováno v: Proteomes, Vol 6, Iss 2, p 17 (2018)

Over the years, the scientific community has explored myriads of theories in search of the etiology and a cure for inflammatory bowel disease (IBD). The cumulative evidence has pointed to the key role of the intestinal barrier and the breakdown of th

Externí odkaz: https://doaj.org/article/add0bedcb8cf4e648f8ac9d87f332131

Zobrazit plný text záznamu

Plný text ve formátu HTML

Current Trends in IBD—Development of Mucosal-Based Biomarkers and a Novel Minimally Invasive Recoverable Sampling System

Autor: Valerie C. Wasinger, Shaoying N. Lee, Rupert W. Leong, Sharat Singh, Jeff Shimizu, Jack Stylli, Robert Hirten, Merodean Huntsman, Emil Chuang, Jeffrey Smith, Christopher Loren Wahl, Bruce E. Sands, Yunki Y. Yau, Vijay Yajnik

Publikováno v: Inflamm Bowel Dis

Despite recent developments in therapy for inflammatory bowel diseases (IBDs), there have been limited advances in diagnostic tools available to aid in disease management. A growing body of evidence suggests that there are important host-microbe inte

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f530dcb09fe3ce0b77c7c95c35464b18
https://doi.org/10.1093/ibd/izab179

Zobrazit plný text záznamu

Randomised clinical trial: safety, pharmacokinetics and pharmacodynamics of trazpiroben (TAK‐906), a dopamine D 2 /D 3 receptor antagonist, in patients with gastroparesis

Autor: George Dukes, Chunlin Chen, Saurabh Gupta, Braden Kuo, Wenwen Zhang, Cecilia Scimia, Emil Chuang, Michael Camilleri

Publikováno v: Alimentary Pharmacology & Therapeutics. 54:267-280

Background Gastroparesis is a chronic gastric motility disorder. Dopamine D2 /D3 receptor antagonists metoclopramide and domperidone are current treatment options but are associated with central nervous system and cardiovascular safety concerns, resp

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::577c25231179dde89d971a00607fa378
https://doi.org/10.1111/apt.16451

Zobrazit plný text záznamu

Plný text ve formátu HTML

Development of a Novel Drug Delivery System to Deliver Drugs Directly to the Colonic Mucosa, Resulting in Improved Efficacy and Reduced Systemic Exposure for the Treatment of Ulcerative Colitis

Autor: Jeff Shimizu, Cheryl A. Stork, Merodean Huntsman, Shaoying N. Lee, Nelson Quintana, Jack Stylli, Emil Chuang, Christopher Loren Wahl, Sharat Singh

Publikováno v: Crohn's & Colitis 360. 3

Despite recent drug approvals for the treatment of inflammatory bowel diseases (IBDs), there remains a high unmet need for new technologies that can increase drug efficacy by improving site-specific drug delivery while reducing systemic exposure. The

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ea630e80dc6c85b9003eac8316d253f9
https://doi.org/10.1093/crocol/otab045

Zobrazit plný text záznamu

Challenges in IBD Research: Environmental Triggers

Publikováno v: Inflammatory Bowel Diseases. 25:S13-S23

Environmental triggers is part of five focus areas of the Challenges in IBD research document, which also includes preclinical human IBD mechanisms, novel technologies, precision medicine and pragmatic clinical research. The Challenges in IBD researc

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f5453c10322afeb90e46be787c940794
https://doi.org/10.1093/ibd/izz076

Zobrazit plný text záznamu

Alosetron versus traditional pharmacotherapy in clinical practice: effects on resource use, health-related quality of life, safety and symptom improvement in women with severe diarrhea-predominant irritable bowel syndrome

Autor: William D. Chey, Emil Chuang, Reshma Shringarpure, Kevin W Olden, Jean Paul Nicandro, David L. Earnest

Publikováno v: Current Medical Research and Opinion. 35:461-472

Severe diarrhea-predominant irritable bowel syndrome (IBS-D) is associated with decreased health-related quality of life (HRQOL) and increased health care costs. Treatment recommendations for IBS-D often start with traditional pharmacotherapy (TP), w

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a6822a7ad6feb6b39c1bd32e6f600997
https://doi.org/10.1080/03007995.2018.1533456

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání